Hjem › Lungecancer › Pennsylvania › Reading
Lungecancer kliniske forsøg i Reading, PA
11 studier for Lungecancer søger deltagere på steder i og omkring Reading (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi væk
- Ephrata Cancer Center, Ephrata · 17 mi væk
- Sechler Family Cancer Center, Lebanon · 26 mi væk
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
- Penn State Health Saint Joseph Medical Center, Reading
- Reading Hospital, West Reading · 1 mi væk
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi væk
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- Ephrata Cancer Center, Ephrata · 17 mi væk
- Sechler Family Cancer Center, Lebanon · 26 mi væk
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi væk
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekruttererFase 3
- Reading Hospital - McGlinn Cancer Institute, West Reading · 1 mi væk
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi væk
- Ephrata Cancer Center, Ephrata · 17 mi væk
- Sechler Family Cancer Center, Lebanon · 26 mi væk
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Ephrata Cancer Center, Ephrata · 17 mi væk
- Sechler Family Cancer Center, Lebanon · 26 mi væk
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Ephrata Cancer Center, Ephrata · 17 mi væk
- Sechler Family Cancer Center, Lebanon · 26 mi væk
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Ephrata Cancer Center, Ephrata · 17 mi væk
- Sechler Family Cancer Center, Lebanon · 26 mi væk
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RekruttererObservationsstudie
- US Digestive Health at Wyomissing, Wyomissing · 2 mi væk
Lungecancer forsøg i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Washington, DC41 studier
- Arlington, VA41 studier
- Chicago, IL41 studier
- Nashville, TN40 studier
- Baltimore, MD40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Reading
- Ikke-småcellet lungecancer9 studier
- Akut myeloid leukæmi5 studier
- Brystkræft5 studier
- Forstyrrelser med overdreven søvnighed5 studier
- Prostatakræft4 studier
- Kræft (alle typer)4 studier
- Colorektal kræft3 studier
- Narkolepsi3 studier
- Søvnforstyrrelser3 studier
- Træthed3 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.